Welcome to our dedicated page for Insmed SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Insmed Incorporated (INSM) brings together the company’s official disclosures to U.S. regulators, offering investors a structured view of its financial condition, material events, and risk factors. As a global biopharmaceutical company focused on serious and rare diseases, Insmed uses filings such as Forms 10-K, 10-Q, and 8-K to report on the performance of its commercial products, the status of its clinical programs, and significant corporate developments.
In periodic reports like the Form 10-K and Form 10-Q, readers can expect detailed discussions of product revenues from therapies such as ARIKAYCE and BRINSUPRI, research and development spending across respiratory, immunology & inflammation, and gene therapy programs, and commentary on liquidity, capital resources, and risks associated with drug development and commercialization. These filings also describe the company’s manufacturing arrangements, intellectual property portfolio, and broader business strategy within pharmaceutical preparation manufacturing.
Current reports on Form 8-K provide timely updates on specific events, including FDA and European Commission approvals of BRINSUPRI, topline clinical results from studies like the Phase 2b BiRCh trial in chronic rhinosinusitis without nasal polyps, and acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory indications. Earnings-related 8-Ks furnish quarterly financial results, while other items may address regulatory milestones, changes in development plans, or key conference presentations.
Stock Titan’s platform enhances these documents with AI-powered summaries that explain complex sections of lengthy filings in accessible language. Users can quickly understand how new data or regulatory decisions may affect Insmed’s product portfolio, pipeline, and financial profile, while still having direct access to the underlying EDGAR-sourced documents for deeper analysis.
JPMorgan Chase & Co. filed an amendment to Schedule 13G reporting beneficial ownership of 23,014,584 shares of Insmed Incorporated common stock (CUSIP 457669307), representing 10.8% of the class. The filing breaks down voting and dispositive powers: 20,997,990 shares with sole voting power and 22,971,006 shares with sole dispositive power; smaller amounts are held with shared powers. The filing lists affiliated entities through which holdings are held, including J.P. Morgan Trust Company of Delaware, J.P. Morgan Securities LLC, JPMorgan Chase Bank NA, and various asset management and international affiliates. The filing certifies the shares are held in the ordinary course of business and not for the purpose of influencing control.
Form 144 filed for Insmed, Inc. (INSM) reporting a proposed sale of common stock. The notice lists a proposed sale of 186,648 shares through Merrill Lynch (Washington, DC) with an aggregate market value of $26,935,498 and total shares outstanding of 211,374,786. The shares to be sold were acquired on 09/02/2025 under a stock plan and the payment/settlement date is the same day. The filing also discloses that the reporting person, Martina Flammer, sold 55,564 shares during the past three months for aggregate gross proceeds of $5,190,291 across four transactions dated 06/03/2025 to 08/04/2025. The form includes the standard representation that the seller is not aware of undisclosed material adverse information.
Insmed, Inc. reported a Form 144 notice for the proposed sale of 24,272 common shares through Merrill Lynch on Nasdaq, with an aggregate market value of $3,491,647.00 and an approximate sale date of 09/02/2025. The filing lists multiple stock-plan acquisitions by the seller throughout 2024–2025 totaling 31,272 shares acquired (individual grants dated 07/08/2024, 01/04/2025, 01/06/2025, 01/07/2025, 02/05/2025 and 09/02/2025). It also discloses sales by the same person during the past three months: 933, 748, 1,879 and 1,448 shares generating stated gross proceeds of $95,617; $72,114; $138,050; and $103,532 respectively. The filer certifies no undisclosed material adverse information and follows the Rule 144 notice requirements.
Insmed, Inc. (INSM) Form 4 shows Director Melvin Sharoky reported a sale of 10,000 shares of Insmed common stock on 08/20/2025 at a reported price of $129.50 per share. After the sale, the reporting person beneficially owns 274,516 shares, held directly and indirectly through various entities and UTMA custodial accounts.
The filing lists multiple indirect holdings: 100 shares held for Owen F. Paley UTMA/FL, 900 by Baby Gator LLC, 10,000 by Padonia, LLC, and additional amounts held for family members and custodial accounts. The report was signed by Melvin Sharoky via attorney-in-fact on 08/21/2025.
Insmed Inc. insider sale disclosure: The company's Chief Operating Officer, Roger Adsett, reported selling a total of 25,000 shares of Insmed common stock on 08/19/2025 in two transactions. The filings show 20,193 shares sold at a weighted-average price of $127.42 (range $127.00–$127.99) and 4,807 shares sold at a weighted-average price of $128.27 (range $128.00–$128.72). After these sales, the report lists beneficial ownership of 110,444 shares in one line and 105,637 shares in another line, each reported as direct ownership. The Form 4 was signed via power of attorney.
Insmed Inc. insider transactions by Chair and CEO William Lewis show option exercises and multiple stock sales executed under a 10b5-1 plan on 08/18/2025. The filing reports the exercise of 6,865 stock options at an exercise price of $10.85 and the acquisition of 6,865 common shares via that exercise. On the same date the reporting person sold a total of 6,865 common shares in separate sell transactions: 2,968 shares at a weighted average price of $127.59, 2,481 shares at $128.76, and 1,416 shares at $129.47. After these transactions the reporting person beneficially owns 303,911 shares indirectly and 50,500 shares indirectly via two trusts.
Insmed, Inc. (INSM) Form 144 filing reports a proposed sale of common stock by an insider. The notice shows 10,000 shares to be sold through Merrill Lynch (Orlando address) with an aggregate market value of $1,294,600.00 and company common shares outstanding listed as 211,374,786. The securities were acquired via stock options on 05/13/2021 (5,865 shares) and 05/22/2024 (13,192 shares). A sale of 10,000 shares by Melvin Sharoky on 08/12/2025 is also reported with gross proceeds of $1,215,350.00. The filer certifies no undisclosed material adverse information. Specific filing date is not provided in the content.
Insmed, Inc. (INSM) Form 144 notifies market participants that an insider intends to sell 25,000 shares of common stock through Merrill Lynch on 08/19/2025, with an aggregate market value of $3,188,795.00. The filing shows total outstanding shares of 211,374,786, indicating the proposed sale is a small fraction of the float. The shares to be sold were principally acquired through the company's stock plan between 2020 and 2025, with specific grant lots listed. The filer also reported two recent open-market sales in June 2025 totaling 12,546 shares for gross proceeds of $1,188,677.00. The notice contains the standard attestation that the seller is not aware of undisclosed material adverse information.
Insmed, Inc. (INSM) filed a Form 144 proposing the sale of 6,865 common shares under Rule 144, with an approximate aggregate market value of $881,244, to be sold through Merrill Lynch on NASDAQ on 08/18/2025. The filing states those shares were acquired on 08/18/2025 through stock plan activity and lists prior sales by the same account (William Lewis and William Lewis TTEE) totaling multiple transactions from 05/20/2025 through 08/04/2025, including a large sale of 129,805 shares on 06/16/2025 generating $13,027,678. The notice includes the standard Rule 144 attestation that the seller is not aware of undisclosed material adverse information.
Insmed insider stock sales totaling 10,000 shares were reported. The reporting person, identified as Chief People Strategy Officer and an officer/director, sold 3,554 shares at a weighted average around $126.57, 5,746 shares at a weighted average around $127.71, and 700 shares at a weighted average around $128.16, all on 08/14/2025. After these transactions the reporting person beneficially owned 79,764 shares.
The record shows specific price ranges for each block of shares sold and that 357 of the remaining shares were acquired through the company’s 2018 Employee Stock Purchase Plan. The filing includes a signed power of attorney for the submission. All details are reported on Form 4 and limited to these transactions and resulting ownership.
FAQ
What is the current stock price of Insmed (INSM)?
What is the market cap of Insmed (INSM)?
